# EDIT — slm-full-cpu

## Metadata

ticker: EDIT
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 546abc0b83d00881ac876a4f4c3bd46a4940d0c022773175e708e709125c9115
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 725, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 182.981, "latency_s_total": 182.981, "parse_failure": 0, "prompt_tokens": 2385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 540, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 145.352, "latency_s_total": 145.352, "parse_failure": 0, "prompt_tokens": 2374, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 123, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 65.055, "latency_s_total": 65.055, "parse_failure": 0, "prompt_tokens": 632, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 159, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 84.008, "latency_s_total": 84.008, "parse_failure": 0, "prompt_tokens": 626, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 233, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 94.988, "latency_s_total": 94.988, "parse_failure": 0, "prompt_tokens": 612, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 160, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 86.314, "latency_s_total": 86.314, "parse_failure": 0, "prompt_tokens": 805, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 986, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 115.156, "latency_s_total": 115.156, "parse_failure": 0, "prompt_tokens": 1728, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.79,
  "currency": "USD",
  "market_cap": 428488288.0,
  "forward_pe": -3.7045395,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "financial_currency": "USD",
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin_pct": -157.32,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker EDIT, here are the key takeaways regarding the company's financial position, operational status, and risks:

**Financial Position and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** The company requires substantial additional capital to sustain operations. If unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce, or eliminate research, product development, or commercialization efforts.
*   **Cash Runway:** Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027.
*   **Limited External Sources:** The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with BMS and retained portions of contingent upfront payments under a license agreement with Vertex.

**Operational Status and Development**
*   **Preclinical Stage:** The company’s most advanced research programs are currently in the preclinical testing stages. It expects it will be many years, if ever, before a product candidate is ready for commercialization.
*   **Focus on EDIT-401:** Expenses are expected to increase significantly as the company continues research, development, and preclinical studies for EDIT-401, and potentially initiates clinical trials.
*   **Revenue Timeline:** Commercial revenues are not expected for years, if at all. The company does not expect to generate substantial product revenues until it can successfully identify candidates, complete trials, obtain marketing approval, and commercialize medicines.

**Risks and Challenges**
*   **Profitability Uncertainty:** The company may never achieve or maintain profitability. Even if profitability is achieved, it may not be sustainable on a quarterly or annual basis. Failure to remain profitable could decrease company value and impair the ability to raise capital or continue operations.
*   **Regulatory and Development Costs:** Costs may increase beyond expectations if regulatory authorities (such as the FDA or EMA) require additional clinical studies. The process of identifying candidates and conducting trials is time-consuming, expensive, and uncertain.
*   **Economic and Political Risks:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.
*   **Dilution and Restrictions:** Raising additional capital through public or private equity offerings may cause dilution to stockholders, restrict operations, or require the relinquishment of rights to technologies or product candidates.

**Funding Sources**
*   Historically, operations have been financed through public offerings of common stock, collaborations with BMS (via Juno Therapeutics), payments from a terminated alliance with Allergan, payments from DRI Healthcare Acquisitions LP, and license agreements with Vertex.
*   Future financing is expected to come from a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to incur significant expenses and increasing operating losses for the foreseeable future and may never achieve or maintain profitability.
*   **Need for Substantial Funding:** The company will need substantial additional funding to support ongoing activities, including preclinical studies and clinical trials for EDIT-401 and other product candidates. If unable to raise capital when needed, the company may be forced to delay, reduce, or eliminate research and product development programs or commercialization efforts. Existing cash and cash equivalents are expected to fund operations only into the third quarter of 2027.
*   **Regulatory and Development Risks:** The company is currently in the preclinical testing stages for its most advanced research programs. Expenses could increase beyond expectations if regulatory authorities require additional clinical or other studies. Identifying and developing product candidates is a time-consuming, expensive, and uncertain process, and the company may never generate the necessary data to obtain marketing approval.
*   **Economic and Political Conditions:** Unfavorable national or global economic conditions, political unrest, or global financial crises could adversely affect the business by causing volatility in capital and credit markets, weakening demand for products, straining suppliers, or making it difficult to raise additional capital on acceptable terms.
*   **Commercialization Risks:** Even if products receive marketing approval, the company may not become profitable. Commercialization expenses related to sales, marketing, manufacturing, and distribution could be significant. The company may also need to raise additional funds sooner if it chooses to pursue additional indications, geographies, or expand more rapidly than anticipated.
*   **Intellectual Property and Collaboration Dependencies:** The company’s future capital requirements depend on factors such as the success of collaborations (e.g., with Bristol Myers Squibb and Vertex Pharmaceuticals), the costs of maintaining intellectual property, and the ability to establish healthcare coverage and reimbursement for approved products.
*   **Dilution and Operational Restrictions:** Raising additional capital through equity offerings, debt financings, or other arrangements may cause dilution to stockholders, restrict operations, or require the company to relinquish rights to its technologies or product candidates.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc. (EDIT) currently trades at $2.79 with a market capitalization of approximately $428.5 million. The company reported revenue of $47.0 million but faces significant profitability challenges, evidenced by a net loss of $73.9 million and a negative profit margin of -157.32%. Consequently, the forward P/E ratio is negative, reflecting ongoing operational losses rather than earnings generation. This financial profile indicates a high-risk investment profile typical of early-stage biotechnology firms reliant on external capital to fund development.

### Recent Developments

Editas Medicine, Inc. (EDIT) continues to face significant financial headwinds, evidenced by a net loss of $73.9 million and a negative profit margin of -157.32%, underscoring the company's reliance on external capital to sustain operations. The recent filing of the 2026 Annual Report (10-K) on March 9, 2026, highlights persistent risks related to the need for additional funding and the uncertainty of achieving projected milestones. With the stock trading near its 52-week low of $1.66 at $2.79, investors should remain cautious as the company navigates a challenging path toward profitability without immediate catalysts from recent news or product approvals.

### SEC Filing Highlights
Editas Medicine reported net losses of $160.1 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it remains in the preclinical stage with no commercial revenues. The company’s existing cash runway is projected to sustain operations only through the third quarter of 2027, necessitating substantial additional capital to fund ongoing research and potential clinical trials for EDIT-401. Primary future funding relies on contingent payments from collaborations with BMS and Vertex, alongside potential equity or debt financings that may result in significant shareholder dilution. Management warns that the company may never achieve profitability and faces risks of delaying or eliminating development efforts if capital is not raised on attractive terms.

### Risk Factors

*   **Substantial Capital Requirements and Liquidity Risk:** The company has a history of significant net losses and an accumulated deficit of $1.6 billion as of December 31, 2025. Current cash reserves are projected to fund operations only through the third quarter of 2027, necessitating substantial additional funding; failure to secure capital could force delays or cancellations of critical research and development programs.
*   **High Uncertainty in Product Development and Regulatory Approval:** As most advanced programs remain in preclinical stages, there is no guarantee that EDIT-401 or other candidates will generate sufficient data to obtain marketing approval. The development process is expensive and time-consuming, with risks of unexpected cost increases or regulatory hurdles that could prevent commercialization.
*   **Commercialization and Profitability Challenges:** Even if products receive approval, the company may never achieve profitability due to high commercialization expenses related to sales, manufacturing, and distribution. Success is also heavily dependent on establishing healthcare coverage and reimbursement, as well as the continued success of key collaborations with partners like Bristol Myers Squibb and Vertex Pharmaceuticals.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a preclinical-stage biotechnology firm focused on CRISPR-based therapies, currently navigating a precarious financial position marked by a $1.6 billion accumulated deficit and a cash runway extending only through the third quarter of 2027. The stock is notable for its extreme valuation risk, trading near multi-year lows as the company faces imminent liquidity constraints and the high probability of dilutive capital raises to fund EDIT-401. The single most critical near-term variable is the company’s ability to secure sufficient external financing or collaboration payments to avoid halting development efforts before achieving commercial viability.

### Outlook
The directional outlook for Editas Medicine is cautiously cautious, characterized by severe liquidity constraints and binary execution risk. The primary headwind is the impending cash runway expiration in the third quarter of 2027, which creates immediate pressure for capital raising that will likely dilute existing shareholders. Tailwinds are limited to the potential success of the EDIT-401 program and the realization of contingent payments from strategic partners like BMS and Vertex. Investors should monitor the company’s progress in securing bridge financing or new partnerships as the key variable; successful execution would stabilize the balance sheet and extend the timeline for clinical milestones, while failure to raise capital on favorable terms would likely result in the suspension of development activities and a further deterioration of shareholder value.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "$1.6 billion accumulated deficit"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "As of December 31, 2025, the accumulated deficit stood at $1.6 billion."

---

CLAIM: "cash runway extending only through the third quarter of 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027."

---

CLAIM: "trading near multi-year lows"
LABEL: UNSUPPORTED
REASON: The source data provides only a 52-week high ($4.537) and 52-week low ($1.66), with no multi-year historical price data to verify whether the current price of $2.79 constitutes a "multi-year low."

---

CLAIM: "EDIT-401" (as the named product milestone/program)
LABEL: SUPPORTED
REASON: EDIT-401 is explicitly named in the RAG SEC Highlights, Risk Factors, and the pre-written SEC Filing Highlights and Risk Factors sections as the company's primary development program.

---

**OUTLOOK**

---

CLAIM: "cash runway expiration in the third quarter of 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state cash is expected to fund operations "into the third quarter of 2027."

---

CLAIM: "contingent payments from strategic partners like BMS and Vertex"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with BMS and retained portions of contingent upfront payments under a license agreement with Vertex."

---

CLAIM: "EDIT-401 program" (as a named tailwind/milestone)
LABEL: SUPPORTED
REASON: EDIT-401 is explicitly identified in the RAG SEC Highlights as the focus of ongoing research and potential clinical trials, and is named across multiple pre-written sections.

---

*No additional quantitative figures, price targets, specific ratios, percentages, or other forward-looking numbers appear in the Executive Summary or Outlook sections beyond those evaluated above.*
